According to filings with the U.S. Securities and Exchange Commission, Dynocardia is raising $6,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Mohan Thanikachalam played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Dynocardia
Dynocardia is a biomedical device development company committed to satisfying critical unmet needs to improve healthcare worldwide. ViTrack, our lead diagnostic device, is powered our proprietary technology making it the only stand-alone, cuff-less device that allows for continuous, non-invasive blood pressure (cNIBP) measurement. Unlike conventional occlusive devices, ViTrack offers direct, beat-to-beat measurement of blood pressure that is wrist-wearable, mobile, and easy to use, with the accuracy of intra-arterial lines. ViTrack, with data-rich capability that includes heart rate, heart rhythm, and respiratory parameters in addition to blood pressure, enables early intervention prior to acute events.

To learn more about Dynocardia, visit http://www.dynocardia.care/

Contact:
Mohan Thanikachalam, President and Chief Executive Officer
617-639-5569

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.